



**CONSOLIDATED FINANCIAL STATEMENTS**

**SEPTEMBER 30, 2020 AND 2019**

*CPAS / ADVISORS*



# DEACONESS HEALTH SYSTEM

## TABLE OF CONTENTS SEPTEMBER 30, 2020 AND 2019

---

|  | Page |
|--|------|
| <b>Report of Independent Auditors</b> .....  | 1    |
| <b>Consolidated Financial Statements</b>   |      |
| Consolidated Balance Sheets.....   | 3    |
| Consolidated Statements of Operations .....  | 5    |
| Consolidated Statements of Changes in Net Assets.....  | 6    |
| Consolidated Statements of Cash Flows .....  | 7    |
| Notes to Consolidated Financial Statements.....  | 8    |
| <b>Reporting Under <i>Government Auditing Standards</i></b>  |      |
| Report of Independent Auditors on Internal Control Over<br>Financial Reporting and on Compliance and Other Matters<br>Based on an Audit of the Financial Statements Performed<br>In Accordance with <i>Government Auditing Standards</i> ..... | 38   |

---



Blue & Co., LLC / 500 N. Meridian Street, Suite 200 / Indianapolis, IN 46204  
main 317.633.4705 fax 317.633.4889 email blue@blueandco.com

## REPORT OF INDEPENDENT AUDITORS

Board of Directors  
Deaconess Health System  
Evansville, Indiana

We have audited the accompanying consolidated financial statements of Deaconess Health System (the System), which comprise the consolidated balance sheets as of September 30, 2020 and 2019, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. For the year ended September 30, 2020, we also conducted our audit in accordance with the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the System's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the System's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the System as of September 30, 2020 and 2019, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Board of Directors  
Deaconess Health System  
Evansville, Indiana

Change in Accounting Principles

As discussed in Note 2 to the consolidated financial statements, effective October 1, 2019, the System early adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)* and adopted FASB ASU No. 2016-18, *Statement of Cash Flows – Restricted Cash (Topic 230)* and FASB ASU 2017-07 *Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*. Our opinion is not modified with respect to these matters.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 21, 2020, on our consideration of the System's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the System's internal control over financial reporting and compliance.

**Blue & Co., LLC**

Indianapolis, Indiana  
December 21, 2020

## DEACONESS HEALTH SYSTEM

### CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2020 AND 2019

| <b>ASSETS</b>                             |                  |                  |
|---|------------------|------------------|
|   | 2020             | 2019             |
| <b>Current assets</b>                     |                  |                  |
| Cash and cash equivalents                 | \$ 290,517,629   | \$ 120,843,990   |
| Funds held by trustee                     | 3,777,593        | 78,838           |
| Patient accounts receivable               | 172,248,714      | 144,900,804      |
| Estimated third-party payor settlements   | 921,122          | -0-              |
| Inventories                               | 12,628,347       | 8,308,038        |
| Prepaid expenses and other current assets | 35,504,980       | 31,008,446       |
| Total current assets                      | 515,598,385      | 305,140,116      |
| <b>Investments limited as to use</b>      |                  |                  |
| Funds held by trustee                     | 3,132,868        | -0-              |
| Board designated funds                    | 838,623,038      | 754,960,087      |
| Board designated funds - Foundation       | 10,760,863       | 9,503,392        |
| Donor restricted - Foundation             | 6,133,888        | 6,222,378        |
| Total investments limited as to use       | 858,650,657      | 770,685,857      |
| <b>Property and equipment</b>             |                  |                  |
| Land and improvements                     | 32,302,594       | 32,211,601       |
| Buildings and improvements                | 807,889,020      | 738,250,134      |
| Furniture, fixtures and equipment         | 325,964,224      | 335,987,151      |
|   | 1,166,155,838    | 1,106,448,886    |
| Accumulated depreciation                  | (595,424,753)    | (618,944,866)    |
|   | 570,731,085      | 487,504,020      |
| Construction in progress                  | 34,387,068       | 43,225,798       |
| Total property and equipment, net         | 605,118,153      | 530,729,818      |
| <b>Other assets</b>                       |                  |                  |
| Investments in joint ventures             | 53,972,791       | 59,679,456       |
| Operating lease right-of-use assets       | 57,167,759       | -0-              |
| Goodwill and other intangibles            | 48,506,788       | 48,536,788       |
| Other                                     | 26,809,337       | 35,844,422       |
| Total other assets                        | 186,456,675      | 144,060,666      |
| Total assets                              | \$ 2,165,823,870 | \$ 1,750,616,457 |

See accompanying notes to consolidated financial statements.

**DEACONESS HEALTH SYSTEM**CONSOLIDATED BALANCE SHEETS  
SEPTEMBER 30, 2020 AND 2019**LIABILITIES AND NET ASSETS**

|   | <u>2020</u>             | <u>2019</u>             |
|---|-------------------------|-------------------------|
| <b>Current liabilities</b>                        |                         |                         |
| Accounts payable and other accrued liabilities    | \$ 93,165,878           | \$ 58,683,612           |
| Salaries, wages and related liabilities           | 83,211,329              | 67,274,653              |
| Estimated third-party payor settlements           | -0-                     | 1,203,209               |
| Accrued interest                                  | 1,456,279               | 1,009,455               |
| Other current liabilities                         | 80,004,690              | 81,715                  |
| Current portion of operating lease liabilities    | 14,321,382              | -0-                     |
| Current portion of long-term debt                 | 13,886,773              | 8,515,092               |
| Total current liabilities                         | <u>286,046,331</u>      | <u>136,767,736</u>      |
| <b>Long-term liabilities</b>                      |                         |                         |
| Operating lease liabilities, less current portion | 43,825,798              | -0-                     |
| Long-term debt, less current portion              | 346,744,625             | 339,994,121             |
| Other long-term liabilities                       | 193,976,050             | 109,134,507             |
| Total long-term liabilities                       | <u>584,546,473</u>      | <u>449,128,628</u>      |
| Total liabilities                                 | 870,592,804             | 585,896,364             |
| <b>Net assets</b>                                 |                         |                         |
| Without donor restrictions                        |                         |                         |
| Undesignated                                      | 433,731,606             | 386,791,115             |
| Designated - capital improvements                 | 838,623,038             | 754,960,087             |
| Designated - Foundation                           | 10,760,863              | 9,503,392               |
| Non-controlling interest                          | 5,981,671               | 7,243,121               |
| Total without donor restrictions                  | 1,289,097,178           | 1,158,497,715           |
| With donor restrictions                           | 6,133,888               | 6,222,378               |
| Total net assets                                  | <u>1,295,231,066</u>    | <u>1,164,720,093</u>    |
| Total liabilities and net assets                  | <u>\$ 2,165,823,870</u> | <u>\$ 1,750,616,457</u> |

See accompanying notes to consolidated financial statements.

## DEACONESS HEALTH SYSTEM

### CONSOLIDATED STATEMENTS OF OPERATIONS YEARS ENDED SEPTEMBER 30, 2020 AND 2019

|   | 2020             | 2019 Restated    |
|---|------------------|------------------|
| <b>Revenue and other support</b>                                |                  |                  |
| Patient service revenue   | \$ 1,159,341,843 | \$ 1,104,452,592 |
| Other revenue   | 74,602,333       | 55,818,667       |
| Total revenue and other support                                 | 1,233,944,176    | 1,160,271,259    |
| <b>Expenses</b>   |                  |                  |
| Salaries and wages  | 475,479,929      | 436,660,908      |
| Employee benefits   | 118,863,136      | 108,811,039      |
| Supplies  | 241,147,757      | 220,788,973      |
| Contract services   | 110,339,597      | 109,079,630      |
| Repairs and maintenance   | 42,146,583       | 34,437,457       |
| Depreciation  | 61,633,074       | 57,056,895       |
| Interest  | 12,261,405       | 12,124,836       |
| Utilities   | 14,545,221       | 13,675,686       |
| Other   | 93,115,077       | 78,704,651       |
| Total expenses  | 1,169,531,779    | 1,071,340,075    |
| Income from operations  | 64,412,397       | 88,931,184       |
| <b>Nonoperating revenues (expenses)</b>                         |                  |                  |
| Investment return   | 30,617,186       | 20,776,491       |
| Net unrealized gain on investments                              | 46,718,251       | 4,622,122        |
| Reclassification of net unrealized holding loss                 | -0-              | (4,645,143)      |
| Net periodic pension benefit (cost)                             | (6,426,607)      | 80,658           |
| Excess assets acquired over liabilities assumed                 | 20,704,344       | -0-              |
| Contributions, gifts, and bequests                              | 588,270          | 952,330          |
| Grants  | (1,633,842)      | (1,956,023)      |
| Total nonoperating revenues (expenses)                          | 90,567,602       | 19,830,435       |
| Excess revenues over expenses                                   | 154,979,999      | 108,761,619      |
| <b>Other changes in net assets without donor restrictions</b>   |                  |                  |
| Reclassification of net unrealized holding loss                 | -0-              | 4,645,143        |
| Benefit related changes other than net<br>periodic benefit cost | (10,523,523)     | (46,775,864)     |
| Net assets released from restriction                            | 768,609          | 718,236          |
| Distributions to non-controlling interest                       | (14,625,622)     | (11,074,376)     |
| Change in net assets without donor restrictions                 | 130,599,463      | 56,274,758       |
| <b>Net assets with donor restrictions</b>                       |                  |                  |
| Contributions, gifts and bequests                               | 520,842          | 668,862          |
| Change in beneficial interest in trusts                         | 22,419           | (36,449)         |
| Investment return   | 28,614           | 45,850           |
| Net unrealized gain (loss) on investments                       | 108,244          | (16,133)         |
| Net assets released from restriction                            | (768,609)        | (718,236)        |
| Change in net assets with donor restrictions                    | (88,490)         | (56,106)         |
| <b>Change in net assets</b>                                     | \$ 130,510,973   | \$ 56,218,652    |

See accompanying notes to consolidated financial statements.

## DEACONESS HEALTH SYSTEM

### CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS YEARS ENDED SEPTEMBER 30, 2020 AND 2019

|   | Without Donor Restrictions   |                             | With Donor<br>Restrictions | Total                   |
|---|------------------------------|-----------------------------|----------------------------|-------------------------|
|   | Undesignated<br>& Designated | Non-controlling<br>Interest |                            |                         |
| <b>Net assets</b>   |                              |                             |                            |                         |
| September 30, 2018  | \$ 1,097,377,657             | \$ 4,845,300                | \$ 6,278,484               | \$ 1,108,501,441        |
| Excess revenues over expenses                                   | 95,289,422                   | 13,472,197                  | -0-                        | 108,761,619             |
| Benefit related changes other than net<br>periodic benefit cost | (46,775,864)                 | -0-                         | -0-                        | (46,775,864)            |
| Net assets released from restriction                            | 718,236                      | -0-                         | (718,236)                  | -0-                     |
| Investment return   | -0-                          | -0-                         | 45,850                     | 45,850                  |
| Net unrealized loss on investments                              | -0-                          | -0-                         | (16,133)                   | (16,133)                |
| Reclassification of net unrealized holding loss                 | 4,645,143                    | -0-                         | -0-                        | 4,645,143               |
| Contributions, gifts, bequests and other changes                | -0-                          | -0-                         | 632,413                    | 632,413                 |
| Distributions to non-controlling interest                       | -0-                          | (11,074,376)                | -0-                        | (11,074,376)            |
| Change in net assets  | <u>53,876,937</u>            | <u>2,397,821</u>            | <u>(56,106)</u>            | <u>56,218,652</u>       |
| September 30, 2019  | 1,151,254,594                | 7,243,121                   | 6,222,378                  | 1,164,720,093           |
| Excess revenues over expenses                                   | 141,615,827                  | 13,364,172                  | -0-                        | 154,979,999             |
| Benefit related changes other than net<br>periodic benefit cost | (10,523,523)                 | -0-                         | -0-                        | (10,523,523)            |
| Net assets released from restriction                            | 768,609                      | -0-                         | (768,609)                  | -0-                     |
| Investment return   | -0-                          | -0-                         | 28,614                     | 28,614                  |
| Net unrealized gain on investments                              | -0-                          | -0-                         | 108,244                    | 108,244                 |
| Contributions, gifts, bequests and other changes                | -0-                          | -0-                         | 543,261                    | 543,261                 |
| Distributions to non-controlling interest                       | -0-                          | (14,625,622)                | -0-                        | (14,625,622)            |
| Change in net assets  | <u>131,860,913</u>           | <u>(1,261,450)</u>          | <u>(88,490)</u>            | <u>130,510,973</u>      |
| September 30, 2020  | <u>\$ 1,283,115,507</u>      | <u>\$ 5,981,671</u>         | <u>\$ 6,133,888</u>        | <u>\$ 1,295,231,066</u> |

See accompanying notes to consolidated financial statements.



## DEACONESS HEALTH SYSTEM

### CONSOLIDATED STATEMENTS OF CASH FLOWS YEARS ENDED SEPTEMBER 30, 2020 AND 2019

|  | 2020           | 2019           |
|--|----------------|----------------|
| <b>Operating activities</b>  |                |                |
| Change in net assets   | \$ 130,510,973 | \$ 56,218,652  |
| Adjustments to reconcile change in net assets<br>to net cash flows from operating activities |                |                |
| Depreciation   | 61,633,074     | 57,056,895     |
| Net unrealized gain on investments   | (46,826,495)   | (4,605,989)    |
| Net realized gain on investments   | (19,349,860)   | (6,138,847)    |
| Unrealized loss on interest rate swap  | 361,566        | 774,592        |
| Amortization of debt issue costs and<br>original issue discount/premium                      | (408,243)      | (407,576)      |
| Restricted contributions, gifts and bequests   | (520,842)      | (668,862)      |
| Excess assets acquired over liabilities assumed  | (20,704,344)   | -0-            |
| Distributions to non-controlling interest  | 14,625,622     | 11,074,376     |
| Changes in operating assets and liabilities  |                |                |
| Patient accounts receivable  | (12,091,566)   | (15,560,116)   |
| Inventories  | (4,320,309)    | 1,620,126      |
| Prepaid expenses and other current assets  | 18,872,466     | 16,038,329     |
| Investments in joint ventures and other assets   | 8,031,750      | (20,334,557)   |
| Accounts payable and other accrued liabilities   | (6,630,734)    | (3,511,706)    |
| Salaries, wages and related liabilities  | 15,936,676     | 2,638,992      |
| Estimated third-party payor settlements  | (2,124,331)    | (3,807,265)    |
| Accrued interest   | 446,824        | (27,983)       |
| Other current liabilities  | 79,922,975     | (16,200)       |
| Other long-term liabilities  | 50,573,398     | 44,612,417     |
| Net cash flows from operating activities   | 267,938,600    | 134,955,278    |
| <b>Investing activities</b>  |                |                |
| Purchases of property and equipment  | (73,120,034)   | (55,474,558)   |
| Proceeds from disposal of property and equipment   | 251,625        | -0-            |
| Purchases of board designated funds  | (588,465,804)  | (402,977,202)  |
| Proceeds from sale of board designated funds   | 569,810,227    | 379,173,194    |
| Cash received in acquisition   | 24,554,000     | -0-            |
| Net cash flows from investing activities   | (66,969,986)   | (79,278,566)   |
| <b>Financing activities</b>  |                |                |
| Distributions to non-controlling interest  | (14,625,622)   | (11,074,376)   |
| Restricted contributions, gifts and bequests   | 520,842        | 668,862        |
| Payments on long-term debt   | (10,358,572)   | (7,955,068)    |
| Net cash flows from financing activities   | (24,463,352)   | (18,360,582)   |
| Change in cash and cash equivalents  | 176,505,262    | 37,316,130     |
| <b>Cash and cash equivalents</b>   |                |                |
| Beginning of year  | 120,922,828    | 83,606,698     |
| End of year  | \$ 297,428,090 | \$ 120,922,828 |
| <b>Reconciliation to consolidated balance sheets</b>   |                |                |
| Cash and cash equivalents in current assets  | \$ 290,517,629 | \$ 120,843,990 |
| Funds held by trustee in current assets - restricted   | 3,777,593      | 78,838         |
| Funds held by trustee in investments - restricted  | 3,132,868      | -0-            |
|  | \$ 297,428,090 | \$ 120,922,828 |

See accompanying notes to consolidated financial statements.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

### 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

#### Nature of Operations

Deaconess Health System (the System) is an integrated multi-facility health system providing comprehensive health care services to southern Indiana, southeastern Illinois and western Kentucky, with full-time equivalents in excess of 6,680 within the Tri-State area.

Deaconess Health System, Inc. was formed to coordinate management and strategic planning and provide operational facilities for entities within the System, the most significant of which are Deaconess Hospital, Inc. (the Hospital) and Deaconess Clinic, Inc. (the Clinic), not-for-profit corporations whose missions are to provide quality health care services with a compassionate and caring spirit to persons, families and communities of the Tri-State area.

The board of Deaconess Health System, Inc. is granted the authority to provide overall direction and control of the entities through their respective bylaws. Deaconess Health System, Inc. wholly owns the Clinic, Deaconess Care Integration, LLC, DCI Commercial ACO, LLC, OneCare, LLC, Deaconess Regional Healthcare Services Illinois, Inc., Deaconess VNA Plus, LLC, Deaconess Specialty Physicians, Inc., Deaconess Health Kentucky, Inc., Deaconess Health Gibson, Inc. and is the sole corporate member of the Hospital.

The Clinic is comprised of Deaconess employed physicians practicing primary care and multi-specialty medicine within outpatient physician offices located throughout southern Indiana, southeastern Illinois and western Kentucky and two urgent care centers located in Evansville, Indiana. The facilities provide illness and injury care, preventative care, lab and x-ray services. The Clinic also encompasses the Deaconess Clinical Research Institute which provides drug research studies for the pharmaceutical industry.

Deaconess Care Integration, LLC is as an accountable care organization with the purpose of developing a care delivery model focused on quality metrics and reductions in cost for the Medicare population. DCI Commercial ACO, LLC is a counterpart to Deaconess Care Integration, LLC, but with a focus on the commercial populations. Its purpose is to assist commercial clients with value-based coverage programs. OneCare, LLC was formed to develop a network of participating health care providers and pursue contracts, in concert with the aforementioned accountable care organizations, with provider-owned health plans, commercial payors, employers, providers, suppliers and other third parties to provide high quality, cost-effective and coordinated health care services to their enrollees.

Deaconess Regional Healthcare Services Illinois, Inc. manages activities such as pain management and other ancillary services in Illinois.

Deaconess VNA Plus, LLC provides home health and hospice care services.

Deaconess Specialty Physicians, Inc. (DSP) provides cardiology services to communities in the Tri-State area.

Deaconess Health Kentucky, Inc. (DHK) houses the operations of the System in Kentucky.

Deaconess Health Gibson, Inc. (DHG) provides health care services in Princeton, Indiana and the surrounding communities.

The System, located in Evansville, Indiana, is comprised of general acute care facilities, a mental health facility and more than 40 ambulatory sites. The inpatient services have a combined capacity of 846 intensive care, pediatric, medical/surgical, orthopedic and neurosurgical beds.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

The System holds majority ownership interests in the following entities:

- Progressive Health of Indiana, LLC – 51%
- Tri-State Radiation Oncology, LLC – 51%
- Deaconess Health Plans, LLC – 95%
- Mainspring Managers, LLC – 51%
- Vascmed, LLC – 51%
- OrthoAlign, LLC – 51%
- Healthcare Resource Solutions, LLC – 95%

Progressive Health of Indiana, LLC provides physical, occupational and speech therapy services throughout southern Indiana.

Tri-State Radiation Oncology, LLC provides oncology and cancer services, including radiation therapy, pain management, counseling and rehabilitation.

Deaconess Health Plans, LLC is a preferred provider organization – managed care network formed to encourage collaboration in providing patient service and cost management.

Mainspring Managers, LLC provides neurology services to treat brain, spinal cord and nervous system injuries, diseases and disorders.

Vascmed, LLC provides services and manage the vascular service line of the Hospital.

OrthoAlign, LLC was created to manage the cost and quality of orthopedic procedures performed by the System.

Healthcare Resource Solutions, LLC provides revenue cycle and billing services.

The System also encompasses a charitable Foundation supported by donations from the community. The Foundation, a department of the System, has a separate advisory board that carries out the mission of supporting medical, charitable and educational activities as designated by the donors.

#### Principles of Consolidation

The consolidated financial statements include the accounts of Deaconess Health System and its wholly owned and controlled subsidiaries. All material inter-company accounts and transactions have been eliminated in consolidation. Noncontrolling interest represents the portion of net assets that is owned by investors that are external to and not included in the consolidated financial statements.

#### Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including estimated third-party payor settlements, defined benefit plan obligations and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period and could differ from actual results.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

#### Cash Equivalents and Consolidated Statements of Cash Flows

Cash equivalents are defined as investments in highly liquid debt instruments with an original maturity of three months or less, excluding amounts whose use is limited by arrangements under trust agreements, board designation or by donors. The System maintains its cash in accounts, which at times may exceed federally insured limits. The System has not experienced any losses in such accounts and believes that it is not exposed to any significant credit risk on cash and cash equivalents. Cash equivalents also include restricted cash from funds held by trustee. Additional cash flows information for 2020 and 2019 follows:

|  | 2020          | 2019          |
|--|---------------|---------------|
| Supplemental cash flows information                                    |               |               |
| Cash paid for interest, net  | \$ 12,341,000 | \$ 12,036,000 |
| Property and equipment in liabilities                                  | \$ 3,095,000  | \$ 807,000    |
| Patient accounts receivable obtained through acquisition               | \$ 15,256,000 | \$ -0-        |
| Property and equipment obtained through acquisition                    | \$ 60,058,000 | \$ -0-        |
| Other assets obtained through acquisition                              | \$ 23,369,000 | \$ -0-        |
| Accounts payable assumed through acquisition                           | \$ 38,018,000 | \$ -0-        |
| Other liabilities assumed through acquisition                          | \$ 34,886,000 | \$ -0-        |
| Long-term debt assumed through acquisition                             | \$ 22,889,000 | \$ -0-        |
| Investment in joint venture released in acquisition                    | \$ 6,740,000  | \$ -0-        |
| Cash paid for amounts included in<br>measurement of lease liabilities: |               |               |
| Operating cash flows from operating leases                             | \$ 14,742,000 | \$ -0-        |
| Right-of-use assets obtained in exchange<br>for lease obligations:     |               |               |
| Operating lease  | \$ 73,488,000 | \$ -0-        |

There was no capitalized interest expense, net of interest income for 2020 and 2019.

#### Patient Accounts Receivable

Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and commercial and managed care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends.

Patient accounts receivable can be impacted by the effectiveness of the System's collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The System also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self pay receivables between pure self pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the System has recorded amounts due to third-party.

---

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

#### Patient Service Revenue

Patient service revenue is recorded at the amount that reflects the consideration to which the System expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others, and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the System bills the patients and third-party payors several days after the services are performed or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the System. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The System believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the System receiving inpatient acute care services or patients receiving services in our outpatient centers or in their homes. The System measures the performance obligation from admission as an inpatient or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. The method of reimbursement for the System is primarily fee for service. The timing of revenue and recognition for healthcare services is transferred over time.

Because all of its performance obligations relate to contracts with a duration of less than one year, the System has elected to apply the optional exemption provided in the Financial Accounting Standards Board (the FASB) Accounting Standards Codification (ASC) 606-10-50-14a and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to previously are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The System determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the System's policy, and implicit price concessions provided to uninsured patients. The System determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The System determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

#### Charity Care, Community Benefit and Assistance to the Uninsured

The System provides care to patients regardless of their ability to pay. A patient is classified as a charity patient by reference to certain established policies of the System. Essentially, these policies define charity services as those services for which no payment or reduced payment based upon a graduated scale, is anticipated, based on the Federal Poverty Income Guidelines, published by the Department of Health and Human Services and where incurred charges are considered significant when compared to the income of the patient. Because collection of amounts determined to qualify as charity care is not pursued, such amounts are not reported as revenue.

The System's charity care policy reflects the current economic conditions and other factors unique to the System's customer base. Charity care provided during 2020 and 2019, measured at established rates, was approximately \$70,186,000 and \$69,592,000, respectively. In addition, other programs and services for the benefit of the community are provided. The costs of these programs are included in operating expenses. The System receives reimbursements from certain governmental payors to assist in the funding of charity care.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

Of the System's total expenses reported, an estimated \$23,790,000 and \$23,935,000 arose from providing services to charity patients during 2020 and 2019, respectively. The estimated costs of providing patient assistance services are based on a calculation which applies a ratio of costs to charges to the gross uncompensated charges associated with providing care to charity patients. The ratio of cost to charges is calculated based on the System's total expenses to patient service revenue. The System did not modify its financial assistance policy during 2020, but did during 2019. The System has a policy for uninsured patients with discounted rates similar to contractual payors. Uninsured self pay discounts were an estimated \$21,477,000 and \$31,111,000 in 2020 and 2019, respectively.

### Inventories

Inventories (principally pharmaceuticals and medical supplies) are stated at the lower of cost (first in, first out) or net realizable value.

### Investments Limited as to Use

These investments are recorded at fair value in the consolidated balance sheets. Investments consist of short-term investments (principally cash equivalents), US Government and government agency obligations, marketable debt securities (corporate bonds and fixed income mutual funds), marketable equity securities (common and preferred corporate stock), equity mutual funds, private equity funds, and mortgage backed securities. Fair values for investments are based on quoted market prices. If quoted market prices are not available, fair values are based on quoted market prices of comparable instruments.

Investments limited as to use include assets held by trustees under indenture agreements, amounts set aside by the Board of Directors for future capital improvements, retirement of debt over which the Board retains control and may at its discretion subsequently designate for other purposes and amounts designated by for the Foundation and donor restrictions. Amounts required to meet current liabilities of the System have been classified as current assets.

Private equity investments consist of limited partnerships investing in common stock of small and medium capitalization companies and mutual funds. Investments in those limited partnerships are reported at fair value as determined by the individual manager of each partnership. Although the manager uses its best judgment in estimating the fair value of the investments in the investment funds, there are inherent limitations in any estimation technique. Therefore, the values reported are not necessarily indicative of the amount that the investments funds could realize in a current transaction.

These estimated values may differ significantly from the values that would have been used had a ready market for the investments in the investment funds existed and the difference could be material. Private equity investments totaled approximately \$126,269,000 and \$113,887,000 (14.6% and 14.8% of investment portfolio) as of September 30, 2020 and 2019, respectively.

A decline in the market value of any other-than-trading security below cost that is deemed to be other-than-temporary results in a reduction in carrying amount to fair value. The impairment is charged to excess revenues over expenses and a new cost basis for the security is established. On October 1, 2018, the System reclassified its debt securities to trading securities. As a result, a reclassification of unrealized holding gain/loss of approximately \$4,645,000 was made from other changes in net assets without donor restrictions to nonoperating revenues (expenses) in 2019.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

Investment securities are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of the System's investments could occur in the near term and that such changes could materially affect the amounts reflected in the consolidated financial statements. A critical factor in this evaluation is the length of time and extent to which the market value of the individual security has been less than cost. Other factors considered include recommendations of investment advisors and conditions specific to the issuer or industry in which the issuer operates.

### Property, Equipment and Depreciation

Property and equipment are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable assets, ranging from 3 to 40 years, using the straight-line method. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the System first compares undiscounted cash flows expected to be generated by that asset or group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

### Investments in Joint Ventures

Investments in organizations where the System's ownership percentage is equal to or less than 50% are included in investments in joint ventures on the consolidated balance sheets. Investments in joint ventures approximated \$53,973,000 and \$59,679,000 as of September 30, 2020 and 2019, respectively. The System's portion of income from unconsolidated organizations is reported with other operating revenue and was \$19,200,000 and \$20,812,000 for 2020 and 2019, respectively. A summary of the significant investments in joint ventures follows:

- The System holds a 50% ownership in the Deaconess Women's Hospital of Southern Indiana, LLC d/b/a The Women's Hospital which is a 74-bed facility dedicated to comprehensive women's care, including obstetrics, neonatal intensive care, cancer treatment and infertility and imaging services.
- The System holds a 50% ownership interest in Evansville Surgery Center Associates, LLC providing three locations of multispecialty outpatient surgery centers dedicated to the diagnosis and preoperative, intraoperative and postoperative care of patients.
- The System holds 33.3% of the membership shares in The Healthcare Group, LLC, a preferred provider organization – managed care network. The Healthcare Group, LLC encourages collaboration in providing patient service and cost management.
- The System holds a 27.5% ownership interest in Encompass Health/Deaconess, LLC, d/b/a Encompass Health Deaconess Rehabilitation Hospital, a comprehensive facility dedicated to improving, maintaining or restoring physical strength, cognition and mobility through therapeutic methods and technologies for rehabilitation.
- The System holds an ownership interest in the Tecumseh Health Reciprocal Risk Retention Group which was formed to provide liability insurance, reinsurance and risk management services to the members.
- The System holds an ownership interest in Crossroads Health Services which provides workers' compensation coverage.
- The System holds a 46% ownership interest in LoField Dialysis, LLC which was formed to provide dialysis and related services.

The System, through DHK, held a 33% ownership in Methodist Health located in Henderson and Morganfield, Kentucky. During 2020, the System acquired 100% ownership in Methodist Health.

---

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

### Leases

The System determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities on the consolidated balance sheets. ROU assets represent the System's right to use an underlying asset for the lease term and lease liabilities represent the System's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the System's leases do not provide an implicit rate, the System uses an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the System will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

### Business Combinations and Goodwill and Other Intangibles

The System accounts for a business combination using the acquisition method of accounting, and accordingly, the net assets of the acquired entity are recorded at their estimated fair values at the date of acquisition. Goodwill represents the excess of the purchase price over the fair value of net assets, including amounts assigned to identifiable intangible assets, if any. Goodwill is tested for impairment on an annual basis, or whenever an event occurs or circumstances indicate the carrying value of the goodwill may be impaired. The System performed the required annual impairment test for goodwill as of September 30, 2020 and 2019 using the income approach of calculating the present value of the future cash flows. The System determined no impairment of goodwill existed as of September 30, 2020 and 2019. As of September 30, 2020 and 2019, the System recorded goodwill and other intangibles of approximately \$48,507,000 and \$48,537,000 related to the acquisition of majority owned entities. Included in these totals are other intangibles, net of accumulated amortization of \$330,000 and \$300,000 as of September 30, 2020 and 2019, respectively, related primarily to non-compete and similar agreements. Annual amortization is estimated at \$30,000 over the remaining amortization periods.

Effective July 1, 2020, the System, through DHK, acquired the remaining 67% interest in Methodist Health. With a 33% interest in Methodist Health, the System previously recognized an equity interest of approximately \$6,740,000 through July 1, 2020. Effective September 1, 2020, the System, through DHG, acquired a 100% interest Gibson General Hospital. There was no cash paid by the System for these business combinations. The System recognized excess assets acquired over liabilities assumed of approximately \$20,704,000 in its 2020 consolidated statement of operations. The following is a summary of the assets purchased and liabilities assumed during 2020:

|   |               |
|---|---------------|
| Assets  |               |
| Cash  | \$ 24,554,000 |
| Patient accounts receivable                     | 15,256,000    |
| Other current assets                            | 18,999,000    |
| Property and equipment                          | 60,058,000    |
| Other assets                                    | 4,370,000     |
| Total assets                                    | 123,237,000   |
| Liabilities                                     |               |
| Accounts payable and other                      | (38,018,000)  |
| Other liabilities                               | (34,886,000)  |
| Long-term debt                                  | (22,889,000)  |
| Total liabilities                               | (95,793,000)  |
| Equity interest previously recognized           | (6,740,000)   |
| Excess assets acquired over liabilities assumed | \$ 20,704,000 |

---



## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

#### Debt Issue Costs

Costs incurred in connection with the issuance of debt are amortized over the term of the related debt using the bonds outstanding method. Estimated annual amortization is approximately \$125,000.

#### Other Long-Term Liabilities

Other long-term liabilities include obligations related to the unfunded status of defined benefit plans, other employee benefit programs, derivative liabilities related to an interest rate swap and the long-term portion of accelerated payments received under the Medicare program.

#### Net Assets

Net assets without donor restrictions are comprised of net assets that are undesignated, board designated and held by non-controlling interest. The following net assets without donor restrictions were board designated as of September 30, 2020 and 2019:

|                      | 2020           | 2019           |
|----------------------|----------------|----------------|
| Board designated     |                |                |
| Capital improvements | \$ 838,623,038 | \$ 754,960,087 |
| Foundation           | 10,760,863     | 9,503,392      |
|                      | \$ 849,383,901 | \$ 764,463,479 |

Net assets with donor restrictions include those assets whose use by the System has been limited primarily for capital projects or a specified time period or purpose. Also included are net assets contributed with donor restrictions requiring they be held in perpetuity with income used to support the System's activities. The following is a summary of net assets with donor restrictions as of September 30, 2020 and 2019:

|                               | 2020         | 2019         |
|-------------------------------|--------------|--------------|
| Patient medical care          | \$ 1,314,941 | \$ 1,342,205 |
| Education and scholarship     | 759,910      | 775,666      |
| Capital projects              | 793,634      | 810,089      |
| Beneficial interest in trusts | 1,173,972    | 1,173,972    |
| To be held in perpetuity      | 692,080      | 692,080      |
| Other System support          | 1,399,351    | 1,428,366    |
|                               | \$ 6,133,888 | \$ 6,222,378 |

Net assets were released from restriction during 2020 and 2019 for the following purposes:

|                           | 2020       | 2019       |
|---------------------------|------------|------------|
| Patient medical care      | \$ 236,813 | \$ 210,451 |
| Education and scholarship | 136,853    | 121,420    |
| Capital projects          | 142,929    | 123,064    |
| Other System support      | 252,014    | 263,301    |
|                           | \$ 768,609 | \$ 718,236 |

---

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

#### Contributions

Unconditional promises to give cash and other assets to the System are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received. The gifts are reported as with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, with donor restricted net assets are reclassified as without donor restricted net assets and reported in the consolidated statements of operations as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are included in nonoperating revenues (expenses) in the accompanying consolidated financial statements. In-kind donations are recorded as revenue and expense in the accompanying consolidated financial statements. These donations consist mainly of medical supplies and services which are recorded at their estimated fair values. The System also evaluates whether a contribution is unconditional or conditional based on the absence or presence of barriers and any right of return provisions.

#### Performance Indicator

The consolidated statements of operations include a performance indicator, excess revenues over expenses. Transactions deemed by management to be ongoing, major, or central to the provision of healthcare services are reported as revenue, support, and expenses. Transactions incidental to the provision of patient care services are reported as nonoperating revenues (expenses). Changes in net assets without donor restrictions, which are excluded from the performance indicator, consistent with industry practice include pension related changes other than net periodic pension cost, contributions of long-lived assets (including assets acquired using contributions, which, by donor restriction, were to be used for the purposes of acquiring such assets) and contributions from/distributions to non-controlling interest.

#### Medical Malpractice

The System participates in the Indiana Medical Malpractice Act, IC 34-18 (the Act), which provides a maximum recovery of \$1,650,000 for an occurrence of malpractice until June 30, 2019, and \$1,800,000 thereafter. The Act requires the System to maintain medical malpractice liability insurance in the amount of at least \$400,000 per occurrence (\$8,000,000 in the annual aggregate) until June 30, 2019. Effective July 1, 2019, the Act requires the System to maintain medical malpractice liability insurance in the amount of at least \$500,000 per occurrence (\$10,000,000 in the annual aggregate). The Act also requires the System to pay a surcharge to the State Patient's Compensation Fund (the Fund). The Fund is used to pay medical malpractice claims in excess of per occurrence and the annual aggregate amounts as noted above, under certain terms and conditions. The Fund is on a claims-made basis and as long as this coverage is continuous or replaced with equivalent insurance, claims based on occurrences during its term but reported subsequently will be insured.

The System is a member of a Vermont insurance company, Tecumseh Health Reciprocal Risk Retention Group (THRRRG), as a means to comply with the System's required portion of the insurance coverage pursuant to the Act, as well as its general liability insurance and excess coverage. Membership in THRRRG includes 14 hospitals as of September 30, 2020. Coverage through THRRRG provides protection from liability in an amount not to exceed \$250,000 per incident and aggregate liability protection not to exceed \$7,500,000 per year. In addition, the System maintains a commercial umbrella/excess liability policy with a limit of \$15,000,000 each occurrence, \$15,000,000 aggregate per member and \$30,000,000 total policy aggregate.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

### Income Taxes

Deaconess Health System, Inc., the Hospital, the Clinic, DSP, DHK and DHG are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code and are generally exempt from income taxes. However, they are required to file Federal Form 990 – Return of Organization Exempt from Income Tax, which is an informational return only.

Accounting principles generally accepted in the United States of America require management to evaluate tax positions taken by the System and recognize a tax liability if the System has taken an uncertain position that more likely than not would not be sustained upon examination by various Federal and state taxing authorities. Management has analyzed the tax positions taken by the System and has concluded that as of September 30, 2020 and 2019, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the accompanying consolidated financial statements. The System is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.

The remaining consolidated subsidiaries are organized as limited liability companies, whereby net taxable income is taxed directly to the members of the limited liability companies. Thus, the consolidated financial statements do not include any provision for Federal or state income taxes related to these entities. These entities have filed their Federal and state income tax returns for periods through their most recent fiscal year ends (primarily December 31, 2019). These income tax returns are generally open to examination by the relevant taxing authorities for a period of three years from the later of the date the return was filed or its due date (including approved extensions).

### Advertising Costs

Advertising costs are expensed as incurred. Total expense for 2020 and 2019 was approximately \$1,314,000 and \$1,246,000, respectively.

### Reclassification

Certain 2019 amounts in the consolidated financial statements have been reclassified to conform to the 2020 presentation. The reclassifications have no effect on previously reported net assets or change in net assets.

### Going Concern Evaluation

The System evaluated whether there were conditions or events that raised substantial doubt about the System's ability to continue as a going concern for a period of one year from the date the consolidated financial statements were issued.

### Subsequent Events

The System evaluated events or transactions occurring subsequent to the consolidated balance sheet date for recognition and disclosure in the accompanying consolidated financial statements through the date the consolidated financial statements were issued which was December 21, 2020.

### Recently Issued Accounting Standards

In May 2019, the FASB issued Accounting Standards Update (ASU) 2019-06, *Intangibles—Goodwill and Other (Topic 350), Business Combinations (Topic 805), and Not-for-Profit Entities (Topic 958), Extending the Private Company Accounting Alternatives on Goodwill and Certain Identifiable Intangible Assets to Not-for-Profit Entities*. The accounting alternatives in this ASU, if elected, will reduce for preparers the cost and complexity associated with the subsequent accounting for goodwill and the accounting for certain items that currently are considered to be identifiable intangible assets for not-for-profit entities. A not-for-profit entity that elects the accounting alternative should

---

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

amortize goodwill on a straight-line basis over a period not to exceed ten years, test for impairment upon a triggering event, and have the option to elect to test for impairment at the entity level. This ASU also provides not-for-profit entities with an alternative to subsume into goodwill and amortize customer-related intangible assets that are not capable of being sold or licensed independently from the other assets of a business and all noncompetition agreements acquired. This ASU is effective upon issuance and not-for-profit entities electing to adopt these alternatives do not have to demonstrate preferability.

The System is presently evaluating the effects that these ASUs will have on its future financial consolidated statements, including related disclosures.

### **2. CHANGE IN ACCOUNTING PRINCIPLES**

#### ASU No. 2016-02

On October 1, 2019, the System early adopted the FASB ASU No. 2016-02, *Leases (Topic 842)* (ASU 842). The lease standard in ASC 842 intended to improve financial reporting about leasing transactions by requiring entities to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases, and to provide additional disclosures regarding the leases. Leases with terms (as defined in ASC 842) of twelve months or less are not required to be reflected on an entity's balance sheet. The System applied the modified retrospective approach to all operating lease agreements during adoption. ASC 842 was applied retrospectively to the beginning of the period of adoption through a cumulative-effective adjustment recognized as of October 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with the previous accounting guidance. The adoption of ASC 842 had a material impact on the consolidated balance sheet, but did not have a material impact on the consolidated statement of operations. As of October 1, 2019, the System's total assets and total liabilities increased by approximately \$57,168,000 as a result of ASC 842. The most significant impact was the recognition of ROU assets and operating lease liabilities for operating leases. The System utilized the package of practical expedients allowing the System to not reassess whether any expired or existing contracts contain a lease, the classification for any expired or existing leases or the initial direct costs for any existing leases. The System has also elected to apply an exemption for short term leases whereby leases with initial lease terms of one year or less are not recorded on the consolidated balance sheet.

#### ASU 2016-18

On October 1, 2019, the System adopted the FASB ASU 2016-18, *Statement of Cash Flows (Topic 230) – Restricted Cash*, which requires that restricted cash and cash equivalents be included in beginning and ending cash in the consolidated statements of cash flows. The adoption of this ASU resulted in the inclusion of funds held by trustee of approximately \$79,000 and \$142,000 in cash and cash equivalents for the consolidated statement of cash flows as of September 30, 2019 and October 1, 2018, respectively. There was no impact to the consolidated statements of operations as a result of adopting this ASU.

#### ASU No. 2017-07

On October 1, 2019, the System adopted the FASB ASU 2017-07 *Compensation-Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*. This standard requires entities to report the service cost component in the same line as other compensation costs arising from services rendered during the period and to report all other components of net periodic benefit cost outside of income from operations. The System retrospectively restated the employee benefits expense and net periodic pension cost by removing the net periodic pension benefit/cost from employee benefits expense and separately reporting this outside of income from operations. Service cost included in employee benefits expense for 2020 and 2019 was approximately \$4,122,000 and \$5,828,000, respectively. The System used the practical expedient allowable under the standard which permits the System to use amounts disclosed in the 2019 pension footnote for the prior period restatement.

---

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

The following table is a summary of the restatement for 2019:

| <b>Consolidated statement of operations</b> | September 30, 2019     |            |                  |
|---|------------------------|------------|------------------|
|   | Previously<br>Reported | Adjustment | Restated         |
|   | Expenses               |            |                  |
| Employee benefits                           | \$ 108,730,381         | \$ 80,658  | \$ 108,811,039   |
| Total expenses                              | \$ 1,071,259,417       | 80,658     | \$ 1,071,340,075 |
| Income from operations                      | \$ 89,011,842          | (80,658)   | \$ 88,931,184    |
| Nonoperating revenues (expenses)            |                        |            |                  |
| Net periodic pension benefit                | \$ -0-                 | \$ 80,658  | \$ 80,658        |
| Total nonoperating revenues (expenses)      | \$ 19,749,777          | \$ 80,658  | \$ 19,830,435    |

The 2019 consolidated balance sheet, consolidated statement of cash flows and total change in consolidated net assets were not impacted by the ASU.

#### ASU 2018-08

On October 1, 2019, the System adopted the FASB ASU No. 2018-08, *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made (Topic 958)*. ASU 2018-08 clarifies and improves current guidance about whether a transfer of assets (or the reduction, settlement, or cancellation of liabilities) is a contribution or an exchange transaction. The amendments clarify how an entity determines whether a resource provider is participating in an exchange transaction by evaluating whether the resource provider is receiving commensurate value in return for the resources transferred. Additionally, the amendments in this ASU require that an entity determine whether a contribution is conditional on the basis of whether an agreement includes a barrier that must be overcome and either a right of return on assets transferred or a right of release of a promisor's obligation to transfer assets. Finally, ASU 2018-08 amends the "simultaneous release accounting policy" to allow a not-for-profit entity to recognize a restricted contribution directly in net assets without donor restrictions if the restriction is met in the same period that revenue is recognized. The adoption of ASU 2018-08 did not have a material impact on the 2020 consolidated financial statements.

#### ASU 2018-13

On October 1, 2019, the System early adopted the FASB ASU 2018-13, *Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement*. The amendments in this ASU removed and modified certain disclosure requirements in Topic 820. As such, the fair value measurement disclosures for 2019 have been restated for these changes.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

#### 3. INVESTMENTS

Investments at fair value consisted of the following as of September 30:

|   | 2020           | 2019           |
|---|----------------|----------------|
| Board designated funds  |                |                |
| Cash  | \$ 10,229,624  | \$ 5,092,110   |
| Common stocks   | 192,540,660    | 179,817,965    |
| Mutual funds  | 275,085,561    | 239,499,793    |
| US Government and government agency obligations                 | 40,956,251     | 39,986,238     |
| Corporate bonds   | 125,652,063    | 110,795,812    |
| Mortgage backed securities                                      | 67,889,988     | 65,880,701     |
| Private equity  | 126,268,891    | 113,887,468    |
|   | 838,623,038    | 754,960,087    |
| Funds held by trustee   |                |                |
| Money market mutual funds                                       | 6,910,461      | 78,838         |
| Current portion   | (3,777,593)    | (78,838)       |
|   | 3,132,868      | -0-            |
| Board designated - Foundation and donor restricted - Foundation |                |                |
| Cash  | 329,388        | 63,564         |
| Common stocks   | 1,550,022      | 1,158,897      |
| Mutual funds  | 12,211,599     | 11,640,232     |
| US Government and government agency obligations                 | 16,501         | 67,435         |
| Accrued interest and other                                      | 2,787,241      | 2,795,642      |
|   | 16,894,751     | 15,725,770     |
| Investments limited as to use, net                              | \$ 858,650,657 | \$ 770,685,857 |

Investments reported as current assets are those that the System has made available for use in operations within the next twelve months. Investments limited as to use that are required for obligations classified as current liabilities are also reported in current assets. A detail of investment return for both net assets with and without donor restrictions for 2020 and 2019 is as follows:

|                                       | 2020          | 2019          |
|---------------------------------------|---------------|---------------|
| Interest and dividends and other      | \$ 11,657,506 | \$ 15,458,086 |
| Net realized gain                     | 19,349,860    | 6,138,847     |
| Unrealized loss on interest rate swap | (361,566)     | (774,592)     |
| Investment return, net                | \$ 30,645,800 | \$ 20,822,341 |

The unrealized gain on investments in 2020 and 2019 for net assets without donor restrictions was approximately \$46,718,000 and \$4,622,000, respectively, and is reported under nonoperating revenues (expenses) in the consolidated statements of operations. The unrealized gain on investments for net assets with donor restrictions was \$108,000 in 2020 compared to an unrealized loss of \$16,000 in 2019. The unrealized gain and loss are included in changes in net assets with donor restrictions on the consolidated statements of operations for the respective years.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

Effective October 1, 2018, the System reclassified its debt securities to trading securities. As a result, a reclassification of net unrealized holding loss of approximately \$4,645,000 during 2019 was made from other changes in net assets without donor restrictions to nonoperating revenues (expenses).

See Note "Derivative Financial Instruments – Interest Rate Swaps" for additional information on unrealized gain or loss on interest rate swap.

### 4. FAIR VALUE MEASUREMENTS

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy are described as follows:

- Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the System has the ability to access.
- Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the asset or liability; inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
- Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used as of September 30, 2020 and 2019:

- *Common stocks*: Valued based on the closing price reported on the active market on which the individual securities are traded.
- *Mutual funds and Exchange Traded Funds*: Valued based on quoted net asset value (NAV) of the shares held by the System at year-end. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities and then divided by the number of shares outstanding. The NAV is quoted in an active market.
- *Money market mutual funds*: Valued based at the subscription and redemption activity at a \$1 stable NAV. However, on a daily basis the funds are valued at their daily NAV calculated using the amortized cost of securities.
- *US Government and government agency obligations*: Valued based on the closing price reported on the active market on which the securities are traded.
- *Corporate bonds and mortgage backed securities*: Valued using pricing models maximizing the use of observable inputs for similar securities.
- *Private equity investments*: Valued at the NAV of units of the fund. The NAV, as provided by the investment manager, is used as a practical expedient to estimate fair value. The private equity investments consist of investments in a variety of domestic and foreign equity and debt securities, managed accounts and other investment vehicles that employ diversified styles and strategies. The NAV is based on the fair value of the underlying investments held by the fund less its liabilities. Due to the nature of the investments held by the fund, changes in market conditions and the economic environment may significantly impact the NAV of the fund and, consequently, the fair value of the System's interests in the funds. Although a secondary market exists for these investments, it is not active and individual transactions are typically not observable. When

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

transactions do occur in this limited secondary market, they may occur at discounts to the reported NAV. It is therefore reasonably possible that if the System were to sell these investments in the secondary market, a buyer may require a discount to the reported NAV, and the discount could be significant.

- *Derivative (Interest rate swap agreement)*: Valued using pricing models that are derived principally from observable market data based on discounted cash flows and interest rate yield curves at quoted intervals for the full term of the swap. See the Note disclosure "Derivatives Financial Instruments – Interest Rate Swaps" for additional information related to derivatives.

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2020 and 2019 are as follows:

|   | September 30, 2020    |                |                |         |
|---|-----------------------|----------------|----------------|---------|
|   | Total                 | Level 1        | Level 2        | Level 3 |
| <b>Assets</b>                                   |                       |                |                |         |
| Investments limited as to use                   |                       |                |                |         |
| Money market mutual funds                       | \$ 6,910,461          | \$ -0-         | \$ 6,910,461   | \$ -0-  |
| Common stocks                                   |                       |                |                |         |
| Consumer  | 37,279,531            | 37,279,531     | -0-            | -0-     |
| Financial services                              | 21,675,453            | 21,675,453     | -0-            | -0-     |
| Industrial and materials                        | 26,532,352            | 26,532,352     | -0-            | -0-     |
| Technology                                      | 44,106,448            | 44,106,448     | -0-            | -0-     |
| Healthcare                                      | 25,536,616            | 25,536,616     | -0-            | -0-     |
| Other   | 38,960,282            | 38,960,282     | -0-            | -0-     |
| Total common stocks                             | 194,090,682           | 194,090,682    | -0-            | -0-     |
| Mutual funds                                    |                       |                |                |         |
| Large growth                                    | 37,029,150            | 37,029,150     | -0-            | -0-     |
| Large value                                     | 30,390,135            | 30,390,135     | -0-            | -0-     |
| Large blend                                     | 219,755,511           | 219,755,511    | -0-            | -0-     |
| Other   | 122,364               | 122,364        | -0-            | -0-     |
| Total mutual funds                              | 287,297,160           | 287,297,160    | -0-            | -0-     |
| US Government and government agency obligations | 40,972,752            | 40,972,752     | -0-            | -0-     |
| Corporate bonds                                 |                       |                |                |         |
| Consumer  | 42,571,696            | -0-            | 42,571,696     | -0-     |
| Financial services                              | 33,083,831            | -0-            | 33,083,831     | -0-     |
| Industrial and materials                        | 37,332,739            | -0-            | 37,332,739     | -0-     |
| International                                   | 8,657,500             | -0-            | 8,657,500      | -0-     |
| Other   | 4,006,297             | -0-            | 4,006,297      | -0-     |
| Total corporate bonds                           | 125,652,063           | -0-            | 125,652,063    | -0-     |
| Mortgage backed securities                      | 67,889,988            | -0-            | 67,889,988     | -0-     |
|   | 722,813,106           | \$ 522,360,594 | \$ 200,452,512 | \$ -0-  |
| Cash  | 10,559,012            |                |                |         |
| Private equity (a)                              | 126,268,891           |                |                |         |
| Accrued interest and other                      | 2,787,241             |                |                |         |
|   | <u>\$ 862,428,250</u> |                |                |         |
| <b>Liabilities</b>                              |                       |                |                |         |
| Derivative                                      | \$ 1,053,116          | \$ -0-         | \$ 1,053,116   | \$ -0-  |



## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

|   | September 30, 2019    |                       |                       |               |
|---|-----------------------|-----------------------|-----------------------|---------------|
|   | Total                 | Level 1               | Level 2               | Level 3       |
| <b>Assets</b>                                   |                       |                       |                       |               |
| Investments limited as to use                   |                       |                       |                       |               |
| Money market mutual funds                       | \$ 78,838             | \$ -0-                | \$ 78,838             | \$ -0-        |
| Common stocks                                   |                       |                       |                       |               |
| Consumer  | 36,578,130            | 36,578,130            | -0-                   | -0-           |
| Financial services                              | 22,692,716            | 22,692,716            | -0-                   | -0-           |
| Industrial and materials                        | 27,563,555            | 27,563,555            | -0-                   | -0-           |
| Technology                                      | 34,017,302            | 34,017,302            | -0-                   | -0-           |
| Healthcare                                      | 19,743,869            | 19,743,869            | -0-                   | -0-           |
| Other   | 40,381,290            | 40,381,290            | -0-                   | -0-           |
| Total common stocks                             | 180,976,862           | 180,976,862           | -0-                   | -0-           |
| Mutual funds                                    |                       |                       |                       |               |
| Large growth                                    | 31,055,758            | 31,055,758            | -0-                   | -0-           |
| Large value                                     | 29,604,968            | 29,604,968            | -0-                   | -0-           |
| Large blend                                     | 190,361,326           | 190,361,326           | -0-                   | -0-           |
| Other   | 117,973               | 117,973               | -0-                   | -0-           |
| Total mutual funds                              | 251,140,025           | 251,140,025           | -0-                   | -0-           |
| US Government and government agency obligations | 40,053,673            | 40,053,673            | -0-                   | -0-           |
| Corporate bonds                                 |                       |                       |                       |               |
| Consumer  | 28,559,153            | -0-                   | 28,559,153            | -0-           |
| Financial services                              | 31,697,760            | -0-                   | 31,697,760            | -0-           |
| Industrial and materials                        | 34,305,876            | -0-                   | 34,305,876            | -0-           |
| International                                   | 6,883,211             | -0-                   | 6,883,211             | -0-           |
| Other   | 9,349,812             | -0-                   | 9,349,812             | -0-           |
| Total corporate bonds                           | 110,795,812           | -0-                   | 110,795,812           | -0-           |
| Mortgage backed securities                      | 65,880,701            | -0-                   | 65,880,701            | -0-           |
|   | 648,925,911           | <u>\$ 472,170,560</u> | <u>\$ 176,755,351</u> | <u>\$ -0-</u> |
| Cash  | 5,155,674             |                       |                       |               |
| Private equity (a)                              | 113,887,468           |                       |                       |               |
| Accrued interest and other                      | 2,795,642             |                       |                       |               |
|   | <u>\$ 770,764,695</u> |                       |                       |               |
| <b>Liabilities</b>                              |                       |                       |                       |               |
| Derivative                                      | \$ 691,550            | \$ -0-                | \$ 691,550            | \$ -0-        |

- (a) In accordance with Subtopic 820-10, certain investments that were measured at NAV per share or its equivalent have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented at fair value in the consolidated balance sheets.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

The following tables summarize the private equity investments measured at fair value based on NAV per share as of September 30, 2020 and 2019:

| Investment     | Fair Value            |                       | Unfunded<br>Commitments | Redemption<br>Frequency | Redemption<br>Notice Period |
|----------------|-----------------------|-----------------------|-------------------------|-------------------------|-----------------------------|
|                | 2020                  | 2019                  |                         |                         |                             |
| Private equity | \$ 44,111,438         | \$ 39,786,047         | None                    | Monthly                 | 45 days                     |
| Private equity | 82,157,453            | 74,101,421            | None                    | Daily                   | Daily                       |
|                | <u>\$ 126,268,891</u> | <u>\$ 113,887,468</u> |                         |                         |                             |

Realized gain and loss are reported in the consolidated statements of operations as a component of investment return. Net realized gains of approximately \$19,350,000 and \$6,139,000 were recorded during 2020 and 2019, respectively. Differences between market value and cost of investments are classified as unrealized gains or losses. The unrealized gain or loss is included in earnings for the period attributable to the change in unrealized gain or loss relating to assets held as of September 30, 2020 and 2019 and is reported in the consolidated statements of operations as net unrealized gain or loss on investments. During 2020, the System recognized an unrealized gain of \$46,826,000 and \$4,606,000 which was included in both nonoperating revenues (expenses) and changes in net assets with donor restrictions.

The System holds investments which are exposed to various risks such as interest rate, market, and credit. Due to the level of risk associated with these securities and the level of uncertainty related to changes in the value, it is at least reasonably possible that changes in the various risk factors will occur in the near term that could materially affect the amounts reported in the accompanying consolidated financial statements.

#### 5. PATIENT SERVICE REVENUE, RELATED RECEIVABLES AND ESTIMATED SETTLEMENTS

The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigation and/or allegations concerning possible violations of fraud and abuse statutes and/or regulations by health care providers. Laws and regulations concerning government programs, including Medicare and Medicaid, are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Final determination of compliance with such laws and regulations is subject to future government review and interpretation. Violations may result in significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. The System believes that it is in compliance with all applicable laws and regulations.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the System's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price increased patient service revenue by approximately \$125,000 and \$163,000 in 2020 and 2019, respectively. As of September 30, 2020, Medicare and Medicaid reports have been audited and final settled with the fiscal intermediary through September 30, 2016.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The System also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The System estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. For 2020 and 2019, adjustments were recognized due to changes in the System's estimates of implicit price concessions, discounts, and contractual adjustments for performance obligations satisfied in prior years were not significant. Subsequent changes that are significant and determined to be the result of an adverse change in the patient's ability to pay, determined on a portfolio basis, are recorded as bad debt expense.

Consistent with the System's mission, care is provided to patients regardless of their ability to pay. Therefore, the System has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the System expects to collect based on its collection history with those patients.

Patients who meet the System's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts determined to qualify as charity care are not reported as revenue.

The System has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the following factors: payors, geography, service lines, method of reimbursement, and timing of when revenue is recognized. The following tables provide details of these factors.

The composition of patient service revenue by payor and by service line for 2020 and 2019 is as follows:

|                             | 2020             | 2019             |
|-----------------------------|------------------|------------------|
| Payor type                  |                  |                  |
| Medicare                    | \$ 419,169,346   | \$ 397,602,933   |
| Medicaid                    | 122,226,166      | 119,280,880      |
| Commercial and managed care | 614,491,414      | 584,255,421      |
| Self pay and other          | 3,454,917        | 3,313,358        |
|                             | \$ 1,159,341,843 | \$ 1,104,452,592 |
| Service line                |                  |                  |
| Hospital - inpatient        | \$ 434,652,930   | \$ 426,318,701   |
| Hospital - outpatient       | 484,054,458      | 446,198,847      |
| Physician services          | 240,634,455      | 231,935,044      |
|                             | \$ 1,159,341,843 | \$ 1,104,452,592 |

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

A summary of patient service revenue, including information on service lines, for 2020 and 2019 follows:

|                                      | 2020             | 2019             |
|--------------------------------------|------------------|------------------|
| Patient service revenue              | \$ 3,450,324,728 | \$ 3,114,993,478 |
| Explicit price concessions and other |                  |                  |
| Charity care                         | (70,185,565)     | (69,591,682)     |
| Uninsured self pay discounts         | (21,476,615)     | (31,111,273)     |
| Contractual adjustments              | (2,173,295,266)  | (1,886,399,446)  |
| Total adjustments                    | (2,264,957,446)  | (1,987,102,401)  |
|                                      | 1,185,367,282    | 1,127,891,077    |
| Implicit price concessions           | (26,025,439)     | (23,438,485)     |
| Patient service revenue              | \$ 1,159,341,843 | \$ 1,104,452,592 |

The following is mix of patient accounts receivable and patient service revenue as of September 30, 2020 and 2019 and for the years then ended:

|                             | Receivable |      | Revenue |      |
|-----------------------------|------------|------|---------|------|
|                             | 2020       | 2019 | 2020    | 2019 |
| Medicare                    | 27%        | 32%  | 36%     | 36%  |
| Medicaid                    | 5%         | 5%   | 10%     | 11%  |
| Commercial and managed care | 64%        | 58%  | 53%     | 52%  |
| Self pay and other          | 4%         | 5%   | 1%      | 1%   |
|                             | 100%       | 100% | 100%    | 100% |

The System has agreements with third-party payors that provide for payments at amounts different from its established rates. A summary of the payment arrangements with major third-party payors follows:

#### Medicare

Inpatient acute care services, outpatient services and physician services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic and other factors. Certain outpatient services and defined medical education costs related to Medicare beneficiaries are paid based on cost reimbursement methodologies. The System's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization. Inpatient non-acute care services are generally reimbursed based upon cost reimbursement methodologies.

#### Medicaid and Hospital Assessment Fee and Healthy Indiana Plan Programs

Medicaid services are paid at prospectively determined rates per day or per discharge for inpatients or per occasion of service for outpatients. To the extent that services to Medicare and Medicaid program beneficiaries are reimbursed based on cost reimbursement methodologies, final settlement is determined after submission of annual cost reports and audits thereof by the fiscal intermediary.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

The System participates in the State of Indiana's Hospital Assessment Fee (HAF) Program. The purpose of the HAF Program is to fund the State share of enhanced Medicaid payments and Medicaid Disproportionate Share payments for Indiana hospitals. Previously, the State share was funded by governmental entities through intergovernmental transfers. The Medicaid enhanced payments relate to both fee for service and managed care claims. The Medicaid enhanced payments are designed to follow the patients and result in increased Medicaid rates. The hospitals also started funding the Healthy Indiana Plan (HIP), the State's Medicaid expansion program. The payments related to the HIP Program mirror the Medicaid payments under the HAF Program but the funding includes physician, state administration, and certain non-hospital expenditures. During 2020 and 2019, the System recognized HAF and HIP program expense of approximately \$35,385,000 and \$37,504,000, respectively, which resulted in Medicaid rate increases. HAF and HIP program expense is included in other expenses on the consolidated statements of operations while the Medicaid rate increases are recorded in patient service revenue.

The State of Kentucky has a similar program to fund its Medicaid program. Historically, the Kentucky tax has been 2.5% of patient service revenue received with long-term care services taxed at 2% with an overall annual cap. The provider tax related to Kentucky was approximately \$635,000 for 2020.

The System also entered into payment agreements with certain other commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for payment under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.

### 6. OPERATING LEASES – RIGHT OF USE (ROU) ASSETS AND RELATED LIABILITIES

The System has various operating leases for buildings and equipment. The leases have remaining lease terms through 2033. Several leases contain renewal options. The System is uncertain on whether it will exercise these renewal options and thus has not included these renewal options in the lease term. The components of operating lease ROU assets and liabilities as of September 30, 2020 and related expense for the year ended are as follows:

|                             |                      |
|-----------------------------|----------------------|
| Operating leases            |                      |
| Operating lease ROU assets  | <u>\$ 57,167,759</u> |
| Operating lease liabilities |                      |
| Current portion             | \$ 14,321,382        |
| Long-term                   | <u>43,825,798</u>    |
|                             | <u>\$ 58,147,180</u> |
| Operating lease cost        | <u>\$ 979,421</u>    |

The weighted average remaining lease term for the operating leases was 3.97% as of September 30, 2020. The weighted average discount rate for 2020 was 3.21%. Operating lease expense for 2020 was approximately \$14,742,000.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

The subsequent maturities of the lease liabilities are as follows:

| Year Ending<br>September 30, |                      |
|------------------------------|----------------------|
| 2021                         | \$ 16,176,913        |
| 2022                         | 14,225,804           |
| 2023                         | 12,665,322           |
| 2024                         | 5,805,529            |
| 2025                         | 3,938,158            |
| Thereafter                   | <u>10,433,890</u>    |
| Total payments               | 63,245,616           |
| Imputed interest             | <u>(5,098,436)</u>   |
|                              | <u>\$ 58,147,180</u> |

#### 7. LONG-TERM DEBT

The following is a summary of long-term debt as of September 30, 2020 and 2019:

|  | 2020                  | 2019                  |
|--|-----------------------|-----------------------|
| Hospital Revenue Bonds                   |                       |                       |
| Series 2011A term bonds                  | \$ 11,885,000         | \$ 12,930,000         |
| Series 2012B term bonds                  | 3,400,000             | 4,930,000             |
| Series 2013A term bonds                  | 63,710,000            | 64,615,000            |
| Series 2013B term bonds                  | 13,560,000            | 14,810,000            |
| Series 2013C term bonds                  | 37,945,000            | 39,180,000            |
| Series 2015A term bonds                  | 47,440,000            | 47,770,000            |
| Series 2016A serial bonds                | 18,970,000            | 18,970,000            |
| Series 2016A term bonds                  | 85,860,000            | 85,860,000            |
| Series 2016 Term Loan Agreement          | 50,400,000            | 52,500,000            |
| Other                                    | <u>22,031,795</u>     | <u>469,077</u>        |
|  | 355,201,795           | 342,034,077           |
| Current portion                          | (13,886,773)          | (8,515,092)           |
| Original issue premiums (discounts), net | 7,271,439             | 7,790,201             |
| Debt issue costs                         | <u>(1,841,836)</u>    | <u>(1,315,065)</u>    |
| Long-term debt, net of current portion   | <u>\$ 346,744,625</u> | <u>\$ 339,994,121</u> |

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

| Hospital Revenue Bonds    | Maturity     | Payment Range<br>(in thousands) | Interest     | Rate            |
|---------------------------|--------------|---------------------------------|--------------|-----------------|
| Series 2011A term bonds   | March 2029   | \$770 to \$1,630                | Fixed        | 2.50% to 6.00%  |
| Series 2012B term bonds   | January 2022 | \$800 to \$1,755                | Fixed        | 2.30%           |
| Series 2013A term bonds   | March 2035   | \$470 to \$8,070                | Fixed        | 3.00% to 5.00%  |
| Series 2013B term bonds   | March 2029   | \$1,000 to \$1,735              | Variable (1) | 0.109%          |
| Series 2013C term bonds   | March 2036   | \$250 to \$2,840                | Variable (2) | 1.004%          |
| Series 2015A term bonds   | March 2039   | \$140 to \$20,255               | Fixed        | 3.00% to 5.00%  |
| Series 2016A serial bonds | March 2039   | \$405 to \$1,920                | Fixed        | 3.00% to 5.00%  |
| Series 2016A term bonds   | March 2044   | \$9,760 to \$45,000             | Fixed        | 3.125% to 5.00% |
| Series 2016 term loan     | January 2025 | \$500 to \$2,100                | Fixed        | 2.50%           |

(1) 70% of BBA LIBOR

(2) 67% of BBA LIBOR plus 90 basis points

Included in other long-term debt are liabilities held by DHK and DHG. DHK has a notes payable with a local financial institution with an outstanding balance of approximately \$16,000,000 as of September 30, 2020. The note matures in 2023 with a variable rate of 1.90% as of September 30, 2020 (LIBOR plus 140 basis points with LIBOR floor of 50 basis points) and is secured by assets with a net book value of \$16,000,000. DHG has an obligation through the United States Department of Agriculture of \$6,000,000 with a fixed interest rate of 3.25% maturing in 2048 secured by assets with a net book value of \$6,000,000.

In 2013, the System, the Indiana Finance Authority (the Authority) and Fifth Third Bank entered into Bond Purchase Contracts (the Contracts) whereby Fifth Third purchased from the Authority all of the Series 2012B, 2012C and 2013B bonds in a private placement. The Series 2013C bonds were purchased from the Authority by Bank of America in a private placement.

Under the terms of the Contracts, Fifth Third and Bank of America agreed to hold the Series 2012B and 2012C bonds through the stated bond maturity dates. The Contracts for the Series 2013B and 2013C bonds are through 2023. At the end of the Contract periods for the Series 2013B and 2013C bonds, these bonds could be remarketed to the original holders or to new investors at interest rate options as provided in the bond documents. If the Series 2013B and 2013C bonds cannot be remarketed at the end of the Contract periods, the System would be subject to payment of the remaining principal.

The System entered into an interest rate swap agreement with Fifth Third on the Series 2013B bonds. See the Note disclosure "Derivatives Financial Instruments – Interest Rate Swaps" for additional information.

All of the revenue bonds are secured by a security interest in the System's revenue. The System covenants that it will not permit any lien or security interest on the System facility other than certain permitted encumbrances. In addition, the various agreements require maintenance of certain debt service income ratios, limit additional borrowings, and require compliance with various other restrictive covenants. As of September 30, 2020 and 2019, the System believed it was in compliance with the restrictive covenants.

As of September 30, 2020, the System did not have any significant commitments outstanding related to property and equipment.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

Aggregate maturities of long-term debt are as follows:

| Year Ending<br>September 30, |                       |
|------------------------------|-----------------------|
| 2021                         | \$ 13,886,773         |
| 2022                         | 13,005,000            |
| 2023                         | 13,590,022            |
| 2024                         | 13,785,000            |
| 2025                         | 13,260,000            |
| Thereafter                   | <u>287,675,000</u>    |
|                              | <u>\$ 355,201,795</u> |

#### 8. DERIVATIVE FINANCIAL INSTRUMENTS – INTEREST RATE SWAPS

##### Objectives and Strategies for Using Derivatives

The System makes limited use of derivative financial instruments for the purpose of managing interest rate risk. In particular, forward interest rate swaps (which are designated as cash flow hedges) are used to manage the risk associated with interest rates on variable-rate borrowings and to lower its overall borrowing costs.

As of September 30, 2020 and 2019, the System had outstanding an interest rate swap agreement with Fifth Third, having a notional amount of \$13,560,000 and \$14,810,000, respectively. The agreement effectively changes the System's interest rate exposure on its Series 2013B bonds through March 2029 to a fixed 2.78%. The interest rate swap agreement matures at the time the related long-term debt matures. The System is exposed to credit loss in the event of nonperformance by the other parties to the interest rate swap agreement. However, the System does not anticipate nonperformance by the counterparties. The derivative is not designated as a hedging instrument, and is marked-to-market on the consolidated balance sheet at fair value. The related gains and losses are included in excess revenues over expenses, the performance indicator, for the reporting period. Cash flows from interest rate swap contracts are classified as an operating activity on the consolidated statement of cash flows.

The asset derivatives are reported in the consolidated balance sheets as other assets. The liability derivatives are reported as derivative liabilities in the other long-term liabilities. As of September 30, 2020 and 2019, the fair values of derivative recorded in the consolidated balance sheets are as follows:

|                             | <u>2020</u>    | <u>2019</u>  |
|-----------------------------|----------------|--------------|
| Other long-term liabilities |                |              |
| Derivative liability        | \$ (1,053,116) | \$ (691,550) |

During 2020 and 2019, the amount of gain or loss recognized in the consolidated statements of operations and reported as a component of investment income under nonoperating revenues (expenses) is as follows:

|                                  | <u>2020</u>  | <u>2019</u>  |
|----------------------------------|--------------|--------------|
| Nonoperating revenues (expenses) |              |              |
| Investment return                |              |              |
| Unrealized loss on derivative    | \$ (361,566) | \$ (774,592) |

---



## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

#### 9. DEFINED BENEFIT PENSION PLAN

The System offers a noncontributory defined benefit pension plan covering eligible employees. Benefits are based on each participant's years of service and compensation. Contributions to the plan are based on actuarially determined amounts sufficient to meet the benefits to be paid to plan participants. The defined benefit pension plan is closed to new participants. Participants should refer to the plan documents for more complete information.

With the acquisition of Methodist Health during 2020, the System, through DHK, assumed the defined benefit plan effective July 1, 2019. The following tables set forth the funded status of the benefit plan and amounts recognized in the consolidated financial statements as of September 30, 2020 and 2019 and for the years then ended.

|   | 2020                    |                        |                         | 2019                    |
|---|-------------------------|------------------------|-------------------------|-------------------------|
|   | The System              | DHK                    | Total                   |                         |
| Change in benefit obligation  |                         |                        |                         |                         |
| Benefit obligation, beginning of period   | \$ 311,670,007          | \$ 53,502,746          | \$ 365,172,753          | \$ 277,497,199          |
| Service cost  | 4,121,719               | -0-                    | 4,121,719               | 5,827,597               |
| Interest cost   | 8,763,215               | 341,911                | 9,105,126               | 10,908,400              |
| Plan settlements  | -0-                     | (2,190,806)            | (2,190,806)             | -0-                     |
| Benefits paid   | (8,530,233)             | (139,322)              | (8,669,555)             | (24,353,796)            |
| Actuarial (gain) loss   | 23,983,680              | 2,560,934              | 26,544,614              | 41,790,607              |
| Benefit obligation, end of period   | <u>\$ 340,008,388</u>   | <u>\$ 54,075,463</u>   | <u>\$ 394,083,851</u>   | <u>\$ 311,670,007</u>   |
| Changes in plan assets  |                         |                        |                         |                         |
| Fair value of plan assets, beginning of period  | \$ 211,086,650          | \$ 25,690,982          | \$ 236,777,632          | \$ 221,432,645          |
| Actual return on plan assets  | 17,106,971              | 1,592,639              | 18,699,610              | 6,003,801               |
| Employer contributions  | 8,504,000               | -0-                    | 8,504,000               | 8,004,000               |
| Plan settlements  | -0-                     | (2,190,806)            | (2,190,806)             | -0-                     |
| Benefits paid   | (8,530,233)             | (139,322)              | (8,669,555)             | (24,353,796)            |
| Fair value of plan assets, end of period  | <u>\$ 228,167,388</u>   | <u>\$ 24,953,493</u>   | <u>\$ 253,120,881</u>   | <u>\$ 211,086,650</u>   |
| Funded status   |                         |                        |                         |                         |
| Funded status of the plan, end of period  | <u>\$ (111,841,000)</u> | <u>\$ (29,121,970)</u> | <u>\$ (140,962,970)</u> | <u>\$ (100,583,357)</u> |
| Amounts recognized in the consolidated balance sheets consist of  |                         |                        |                         |                         |
| Other long-term liabilities   | <u>\$ (111,841,000)</u> | <u>\$ (29,121,970)</u> | <u>\$ (140,962,970)</u> | <u>\$ (100,583,357)</u> |
| Amounts not yet reflected in net periodic benefit cost and included in other changes in unrestricted net assets |                         |                        |                         |                         |
| Prior service (cost) credit   | \$ -0-                  | \$ -0-                 | \$ -0-                  | \$ -0-                  |
| Accumulated gain (loss)   | (120,017,299)           | (25,067,323)           | (145,084,622)           | (109,711,490)           |
| Other changes in unrestricted net assets  | (120,017,299)           | (25,067,323)           | (145,084,622)           | (109,711,490)           |
| Cumulative employer contributions in excess (deficit) of net periodic benefit cost                              | 8,176,299               | (4,054,647)            | 4,121,652               | 9,128,133               |
| Net amount recognized in the consolidated balance sheets  | <u>\$ (111,841,000)</u> | <u>\$ (29,121,970)</u> | <u>\$ (140,962,970)</u> | <u>\$ (100,583,357)</u> |

**DEACONESS HEALTH SYSTEM**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
SEPTEMBER 30, 2020 AND 2019

Other pension disclosures for 2020 and 2019 include:

|  | 2020                 |                     |                      | 2019                 |
|--|----------------------|---------------------|----------------------|----------------------|
|  | The System           | DHK                 | Total                |                      |
| Components of net periodic benefit cost  |                      |                     |                      |                      |
| Service cost   | \$ 4,121,719         | \$ -0-              | \$ 4,121,719         | \$ 5,827,597         |
| Interest cost  | 8,763,215            | 341,911             | 9,105,126            | 10,908,400           |
| Expected return on plan assets   | (11,975,834)         | (404,983)           | (12,380,817)         | (14,764,370)         |
| Settlement (gain) loss   | -0-                  | 1,015,563           | 1,015,563            | -0-                  |
| Amortization of (gain) loss  | 8,546,734            | 140,001             | 9,562,297            | 3,775,312            |
| Net periodic benefit cost  | <u>\$ 9,455,834</u>  | <u>\$ 1,092,492</u> | <u>\$ 11,423,888</u> | <u>\$ 5,746,939</u>  |
| Other changes in unrestricted net assets   |                      |                     |                      |                      |
| Net (gain) loss arising during year  | \$ 18,852,543        | \$ 1,373,278        | \$ 20,225,821        | \$ 50,551,176        |
| Amortization of prior service cost   | -0-                  | -0-                 | -0-                  | -0-                  |
| Amortization of gain (loss)  | (8,546,734)          | (1,155,564)         | (9,702,298)          | (3,775,312)          |
| Total other changes in unrestricted net assets   | <u>\$ 10,305,809</u> | <u>\$ 217,714</u>   | <u>\$ 10,523,523</u> | <u>\$ 46,775,864</u> |
| Estimated amounts that will be amortized from other changes in unrestricted net assets over the next fiscal year |                      |                     |                      |                      |
| Amortization of prior service (cost) credit  | \$ -0-               | \$ -0-              | \$ -0-               | \$ -0-               |
| Amortization of gain (loss)  | \$ 9,504,581         | \$ 1,763,209        | 11,267,790           | \$ (8,546,734)       |
| Weighted-average actuarial assumptions to determine benefit obligations of September 30                          |                      |                     |                      |                      |
| Discount rate  | 2.62%                | 2.71%               |                      | 3.13%                |
| Rate of compensation increase  | 3.50%                | N/A                 |                      | 3.50%                |
| Measurement date   | 9/30/20              | 9/30/20             |                      | 9/30/19              |
| Weighted-average actuarial assumptions to determine net periodic benefit cost as of September 30                 |                      |                     |                      |                      |
| Discount rate  | 3.13%                | 2.71%               |                      | 4.22%                |
| Expected long-term rate of return  | 5.70%                | 7.00%               |                      | 6.75%                |
| Rate of compensation increase  | 3.50%                | N/A                 |                      | 3.50%                |
| Additional year end information  |                      |                     |                      |                      |
| Projected benefit obligation   | \$ 340,008,388       | \$ 54,075,463       | \$ 394,083,851       | \$ 311,670,007       |
| Accumulated benefit obligation   | \$ 321,879,761       | \$ 54,075,463       | \$ 375,955,224       | \$ 294,096,427       |
| Fair value of plan assets  | \$ 228,167,388       | \$ 24,953,493       | \$ 253,120,881       | \$ 211,086,650       |

The following is a schedule by year of expected benefit payments for the years after September 30, 2020:

| Year Ending<br>September 30, | The System            | DHK                  | Total                 |
|------------------------------|-----------------------|----------------------|-----------------------|
| 2021                         | \$ 10,223,690         | \$ 2,547,205         | \$ 12,770,895         |
| 2022                         | 11,185,550            | 1,587,504            | 12,773,054            |
| 2023                         | 12,066,213            | 1,775,613            | 13,841,826            |
| 2024                         | 12,927,763            | 1,923,877            | 14,851,640            |
| 2025                         | 13,953,059            | 1,910,506            | 15,863,565            |
| 2026-2030                    | 81,206,985            | 10,959,725           | 92,166,710            |
|                              | <u>\$ 141,563,260</u> | <u>\$ 20,704,430</u> | <u>\$ 162,267,690</u> |

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

Determination of net periodic pension cost for the years ended September 30, 2020 and 2019 is based on assumptions and census data as of January 1, 2020 and 2019, respectively.

The principal long-term determinant of a portfolio's investment return is its asset allocation. The pension benefits plan allocation includes growth assets (60%) and fixed income (40%). In addition, active management strategies have added value relative to passive benchmark returns. The expected long-term rate of return assumption is based on the mix of assets in the plan, the long-term earnings expected to be associated with each asset class, and the additional return expected through active management. This assumption is periodically benchmarked against peer plans.

The amortization of any prior service cost is determined using a straight-line amortization of the cost over the average remaining service period of employees expected to receive benefits under the pension benefits plan.

The weighted-average asset allocations for both plans as of September 30, 2020 and 2019, by asset category, are as follows:

|                          | <u>2020</u> | <u>2019</u> |
|--------------------------|-------------|-------------|
| Equity                   |             |             |
| Mutual funds             | 30%         | 31%         |
| Common/collective trusts | 11%         | 9%          |
| Common stocks            | <u>12%</u>  | <u>13%</u>  |
| Total equity             | 53%         | 53%         |
| Fixed income             |             |             |
| Bonds                    | 27%         | 26%         |
| Common/collective trusts | <u>11%</u>  | <u>13%</u>  |
| Total fixed income       | 38%         | 39%         |
| Cash equivalents         | 4%          | 3%          |
| Private equity           | <u>5%</u>   | <u>5%</u>   |
|                          | <u>100%</u> | <u>100%</u> |

The allocation strategy for the pension benefits plans currently comprises approximately 50% to 70% growth investments (target of 60%) and 30% to 50% fixed-income investments (target of 40%). Within the growth investment classification, the plans asset strategy encompass equity and equity-like instruments that are expected to represent approximately 60% of the System's plans asset portfolio of both public and private market investments. The largest component of these equity and equity-like instruments is public equity securities that are well diversified and invested in U.S. and international companies.

Fair value of mutual funds, exchange traded funds (ETF) and marketable equity securities are based on the quoted prices in active markets. Common/collective trusts are valued at the NAV on a private market that is not active. However, the underlying investments are traded on an active market. The fair value of the private equity funds is valued at the percentage ownership of the NAV as reported to the plan by the individual managers.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

The following is an analysis of fair value of the major classes of pension benefits plan assets of September 30, 2020 and 2019:

|   | 2020           |               |                |
|---|----------------|---------------|----------------|
|   | The System     | DHK           | 2019           |
| Level 1                                   |                |               |                |
| Mutual funds and ETF                      |                |               |                |
| Large blend and value                     | \$ 54,242,302  | \$ 5,289,864  | \$ 53,902,396  |
| Foreign                                   | 14,264,790     | 2,206,802     | 12,407,504     |
| Total mutual funds and ETF                | 68,507,092     | 7,496,666     | 66,309,900     |
| Common stocks                             |                |               |                |
| Financial services                        | 4,953,911      | 1,273,134     | 4,368,329      |
| Industrial and materials                  | 3,340,281      | 679,136       | 3,662,349      |
| Other                                     | 19,738,435     | 9,868,286     | 18,390,740     |
| Total common stocks                       | 28,032,627     | 11,820,556    | 26,421,418     |
| Total Level 1                             | 96,539,719     | 19,317,222    | 92,731,318     |
| Level 2                                   |                |               |                |
| Fixed income bonds                        |                |               |                |
| Domestic                                  | 55,941,379     | 4,661,981     | 52,471,874     |
| High yield                                | 907,338        | -0-           | 653,621        |
| Foreign                                   | 4,205,267      | -0-           | 1,843,041      |
| Total Level 2                             | 61,053,984     | 4,661,981     | 54,968,536     |
| Cash equivalents                          | 9,332,923      | 693,560       | 7,117,858      |
| Common/collective trusts - not classified | 49,739,643     | -0-           | 44,853,420     |
| Private equity - not classified           | 11,501,119     | 280,730       | 11,415,518     |
|   | \$ 228,167,388 | \$ 24,953,493 | \$ 211,086,650 |

See the Note disclosure "Fair Value Measurements" for additional information.

The System expects to contribute in excess of the required funding amounts to its pension benefits plan in 2021 of approximately \$8,004,000. The expected contribution for 2021 for DHK plan is \$3,722,000.

The System also offers a 401k plan to eligible employees where the System makes base contributions to eligible employees based on years of service in addition to matching contributions (ranging from 25% to 60% of employee deferral up to 6% of eligible earnings) based on the eligible employees' contribution to the 401k plan. Total expense for the System's contributions for eligible employees for 2020 and 2019 was approximately \$15,963,000 and \$11,448,000, respectively.

#### 10. RELATED PARTY TRANSACTIONS

The System is a joint-owner of The Women's Hospital. The System owns the building in which The Women's Hospital is located and leases the space to The Women's Hospital currently at approximately \$230,000 per month with an option to increase that amount annually through 2031. The System provides ancillary services (lab, radiology) for The Women's Hospital. Ancillary services provided were approximately \$3,703,000 and \$3,511,000 in 2020 and 2019, respectively.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

The System is a joint owner of Evansville Surgery Center Associates, LLC (Surgery Center). The System recorded contract service expense related to the Surgery Center of approximately \$29,546,000 and \$31,886,000 in 2020 and 2019, respectively. As of September 30, 2020 and 2019, the System had a liability to the Surgery Center of approximately \$4,169,000 and \$4,217,000, respectively.

The System is a joint-owner of Encompass Health Deaconess Rehabilitation Hospital. The System provides ancillary services (lab, radiology) to Encompass Health Deaconess Rehabilitation Hospital. Ancillary services provided were approximately \$919,000 and \$815,000 in 2020 and 2019, respectively.

Related party transactions between the System and other joint ventures in 2020 and 2019 were not significant to the System's overall consolidated financial statements.

### 11. COMMITMENTS AND CONTINGENCIES

#### Litigation

The System is involved in litigation and regulatory matters arising in the course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the System's future financial position, results from operations or cash flows.

#### Health Insurance

The System's employee health care insurance is provided through a combination of insured, self-insured and purchased re-insurance coverage from a commercial carrier. The System maintains an estimated liability for the amount of claims incurred but not reported. Substantially all employees are covered for major medical benefits. The self-insured health coverage carries a stop-loss maximum of \$450,000 per case with no aggregate limit.

### 12. LIQUIDITY AND AVAILABILITY OF RESOURCES

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the 2020 consolidated balance sheet date approximate \$463,688,000 and are comprised of \$290,518,000 in cash and cash equivalents, \$172,249,000 of patient accounts receivable and \$921,000 of estimated third-party settlements. None of the financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the consolidated balance sheet date. Patient accounts receivable are subject to implied time restrictions, but are expected to be collected within one year.

As a part of the System's liquidity management, it has a policy to structure financial assets to be available as its general expenditures, liabilities and other obligations come due. In addition, the System periodically invests excess cash in investments. The System has board designated investments of approximately \$838,623,000 as of September 30, 2020. Although the System does not intend to spend from these board designated funds (other than amounts appropriated for general expenditure), these amounts could be made available, if necessary.

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the 2019 consolidated balance sheet date approximated \$265,745,000 and were comprised of \$120,844,000 in cash and cash equivalents and \$144,901,000 of patient accounts receivable.

## DEACONESS HEALTH SYSTEM

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

#### 13. FUNCTIONAL EXPENSES

The System provides health care services to patients in the community and the surrounding areas. Expenses related to providing these services for 2020 and 2019 are as follows. Fundraising expenses were not significant in 2020 and 2019.

| Expenses                | 2020                   |                             |                  |
|-------------------------|------------------------|-----------------------------|------------------|
|                         | Healthcare<br>Services | General &<br>Administrative | Total            |
|                         | Salaries and wages     | \$ 429,655,819              | \$ 45,824,110    |
| Employee benefits       | 101,568,444            | 17,294,692                  | 118,863,136      |
| Supplies                | 239,073,060            | 2,074,697                   | 241,147,757      |
| Contract services       | 101,584,165            | 8,755,432                   | 110,339,597      |
| Repairs and maintenance | 30,080,721             | 12,065,862                  | 42,146,583       |
| Depreciation            | 41,962,329             | 19,670,745                  | 61,633,074       |
| Interest                | 7,223,771              | 5,037,634                   | 12,261,405       |
| Utilities               | 8,965,892              | 5,579,329                   | 14,545,221       |
| Other                   | 83,437,288             | 9,677,789                   | 93,115,077       |
| Total expenses          | \$ 1,043,551,489       | \$ 125,980,290              | \$ 1,169,531,779 |

  

| Expenses                | 2019 Restated          |                             |                  |
|-------------------------|------------------------|-----------------------------|------------------|
|                         | Healthcare<br>Services | General &<br>Administrative | Total            |
|                         | Salaries and wages     | \$ 394,577,959              | \$ 42,082,949    |
| Employee benefits       | 92,978,936             | 15,832,103                  | 108,811,039      |
| Supplies                | 218,889,431            | 1,899,542                   | 220,788,973      |
| Contract services       | 100,424,176            | 8,655,454                   | 109,079,630      |
| Repairs and maintenance | 24,578,589             | 9,858,868                   | 34,437,457       |
| Depreciation            | 38,846,678             | 18,210,217                  | 57,056,895       |
| Interest                | 7,143,312              | 4,981,524                   | 12,124,836       |
| Utilities               | 8,429,898              | 5,245,788                   | 13,675,686       |
| Other                   | 70,524,590             | 8,180,061                   | 78,704,651       |
| Total expenses          | \$ 956,393,569         | \$ 114,946,506              | \$ 1,071,340,075 |

Certain costs such as salaries and wages and employee benefits have been allocated among healthcare services and general and administrative categories based on actual direct expenditures incurred by departments, locations, and cost centers, and cost allocations based upon time spent by the System's personnel. Other expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include repairs and maintenance, depreciation, and interest, which are allocated based on statistics such as square footage. Although the methods used were appropriate, alternative methods may provide different results.

# DEACONESS HEALTH SYSTEM

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2020 AND 2019

---

### 14. COVID-19 AND GOVERNMENT PROGRAMS

In March 2020, the World Health Organization declared Coronavirus (COVID-19) a pandemic. The continued spread of COVID-19, or any similar outbreaks in the future, may continue to adversely impact the local, regional, national and global economies. The extent to which COVID-19 continues to impact the System's operating results is dependent on the breadth and duration of the pandemic and could be affected by other factors management is not currently able to predict. Impacts include, but are not limited to, additional costs for responding to COVID-19, potential shortages of health care personnel, potential shortages of clinical supplies, loss of, or reduction to, revenue, and investment portfolio declines. Management believes the System is taking appropriate actions to respond to the pandemic. However, the full impact is unknown and cannot be reasonably estimated at the date the consolidated financial statements were issued.

During 2020, Provider Relief Fund (PRF) grants authorized under the Coronavirus Aids, Relief, and Economic Security (CARES) Act were distributed to healthcare providers impacted by the outbreak of the COVID-19 pandemic primarily under Catalog of Federal Domestic Assistance (CFDA) #93.498. Revenues from PRF grants can be recognized to the extent of expenses incurred specific to responding to the COVID-19 pandemic. Eligible expenses must not be reimbursed from another source and not obligated to be reimbursed from another source. PRF grants that are not fully expended on eligible expenses can then be applied to lost revenues as defined by the guidance issued by the grantor. However, the current grantor guidance available to define eligible expenses and, more specifically, lost revenues related to the pandemic is evolving as of the date the consolidated financial statements were issued.

The System received PRF grants of approximately \$40,911,000 during 2020. PRF funds are subject to recoupment by the grantor in the event that the conditions for recognition are not satisfied. The System recognized PRF grants of \$21,178,000 in 2020 in other revenue on the consolidated statements of operations related to eligible expenses incurred. As of September 30, 2020, \$19,733,000 was recorded as refundable advances in other current liabilities on the consolidated balance sheets.

The CARES Act also allowed health care providers to request accelerated and advanced payments for Medicare services. The System received approximately \$116,158,000 of accelerated and advanced Medicare payments under this CARES Act provision through the date the consolidated financial statements were issued. Included on the consolidated balance sheets in other current liabilities and other long-term liabilities was \$60,272,000 and \$55,886,000, respectively.



Blue & Co., LLC / 500 N. Meridian Street, Suite 200 / Indianapolis, IN 46204  
 main 317.633.4705 fax 317.633.4889 email blue@blueandco.com

**REPORT OF INDEPENDENT AUDITORS ON INTERNAL  
 CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS  
 BASED ON AN AUDIT OF THE FINANCIAL STATEMENTS PERFORMED  
 IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS**

Board of Directors  
 Deaconess Health System  
 Evansville, Indiana

Report on the Consolidated Financial Statements

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Deaconess Health System (the System), which comprise the consolidated balance sheet as of September 30, 2020, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 21, 2020.

Internal Control over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the System's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the System's internal control. Accordingly, we do not express an opinion on the effectiveness of the System's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the System's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the System's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of consolidated financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Board of Directors  
Deaconess Health System  
Evansville, Indiana

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the System's internal control or on compliance. This report is an integral part of an audit performed in accordance *with Government Auditing Standards* in considering the System's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

**Blue & Co., LLC**

Indianapolis, Indiana  
December 21, 2020